Navigation Links
Lung cancer survival rates improved through use of individualized chemotherapy

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study published in the September edition of the Journal of Thoracic Oncology (JTO), analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) based on the histoculture drug response assay (HDRA). After seven years of study, researchers concluded that the use of adjuvant (post-operative) chemotherapy based on results of the in vitro HDRA improved the survival and prognosis of patients with NSCLC who had undergone surgery and whose results of the HDRA assay showed chemosensitivity to the specific drugs used for treatment.

The patients' chemosensitivity to cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine and irinotecan were examined by the HDRA assay. The patients in the study were then split into two groups: (1) those whose tumors were sensitive to at least two of the HDRA drugs and received two HDRA positive drugs per chemotherapy session (31 patients) and (2) those whose tumors were sensitive to one or none of the HDRA drugs and were treated with a combination of one HDRA positive drug and one HDRA negative or two HDRA negative drugs per chemotherapy session (34 patients).

The overall five-year survival rate for the prediction sensitive group given two HDRA positive drugs was 82.4 percent. In contrast, the five-year survival rate for the patients whose tumors indicated a low sensitivity or no sensitivity to the HDRA drugs and received one HDRA positive drug and one HDRA negative or two HDRA negative drugs was 40.1 percent. Additionally, the rate of relapse was lower for the patients in the prediction sensitive group. Relapse occurred in 29 percent of patients who were given two HDRA positive drugs per chemotherapy session while it occurred in 55.8 percent of patients who underwent the other treatment.

"Our research concluded that the HDRA assay seems to be useful for the selection of anticancer drugs in chemotherapy," explained lead investigator, Masayuki Tanahashi, MD. However, Dr. Tanahashi and his colleagues recommend further research into this treatment option.


Contact: Colleen Butz
International Association for the Study of Lung Cancer

Related medicine news :

1. Tumor budding identified as predictor for unfavorable outcome in lung cancer
2. Preventive cancer surgeries save womens lives
3. Can Fruits, Veggies Help Ward Off Lung Cancer?
4. Increasing selenium intake may decrease bladder cancer risk
5. Diverse diet of veggies may decrease lung cancer risk
6. Moderate Drinking May Boost Risk of Breast Cancers Return
7. Use the common cold virus to target and disrupt cancer cells?
8. Double-therapy approach effectively inhibited brain cancer recurrence
9. New nuclear breast imaging technologies associated with higher cancer risks
10. Alcohol intake increases certain types of breast cancer
11. Nicotine binding to receptor linked to breast cancer cell growth
Post Your Comments:
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing all ... year? , This question has not been an easy question to answer. Especially when ... and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , 26 november 2015 AAIPharma ... de geplande investering aan van ten minste ... laboratoria en het mondiale hoofdkantoor in ... zal resulteren in extra kantoorruimte en extra ... de groeiende behoeften van de farmaceutische en ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Asia Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise ... the Demand " report to their offering. ... --> Boston scientific and others. ... players including Medtronic, Biotronik, Boston scientific ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology: